登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Estimating willingness to pay for renewable energy in South Korea using the contingent valuation method》

  • 来源专题：能源战略信息监测
  • 编译者： giecinfo
  • 发布时间：2016-04-15

  • The importance of renewable energy as a response to climate change is universally acknowledged. However, its successful implementation requires public approval and cooperation. This study aims to identify the level of renewable energy acceptance in Korea by estimating Korean consumers’ additional willingness to pay (WTP) using the contingent valuation (CV) method, which is the most widely used to analyze consumer preferences. The estimation results indicate that Korean consumers are willing to pay an additional USD 3.21 per month for electricity generated with renewable energy. However, WTP in Korea is low relative to other advanced nations, indicating that these values could be influenced through policies aimed at improving knowledge and acceptance of renewable energy sources among Korean consumers.

240浏览量
原文链接
相关报告

  • 《MedRxiv，3月20日，PREDICTING THE EVOLUTION OF COVID-19 IN PORTUGAL USING AN ADAPTED SIR MODEL PREVIOUSLY USED IN SOUTH KOREA FOR THE MERS OUTBREAK》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-23
    • PREDICTING THE EVOLUTION OF COVID-19 IN PORTUGAL USING AN ADAPTED SIR MODEL PREVIOUSLY USED IN SOUTH KOREA FOR THE MERS OUTBREAK Pedro Teles doi: https://doi.org/10.1101/2020.03.18.20038612 Abstract Since original reports in Wuhan, China, the new coronavirus covid-19 has spread very quickly worldwide, leading the World Health Organization (WHO) to declare a state of pandemic. Moreover, as of the 13th of March 2020, the WHO has announced that the European continent is now the main centre of the pandemic. Many European governments have already implemented harsh measures to attempt to contain the spread of the virus. In Portugal, there are, as of the 18th of March 2020, 642 confirmed cases. In this study, I applied an adapted SIR model previously used in South Korea to model the MERS outbrake, which is also caused by a coronavirus, to estimate the evolution of the curve of active cases in the case of the Portuguese situation. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    192浏览量
    原文链接

  • 《BioRxiv，3月2日，Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-03
    • Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19 Meehyun Ko, So Young Chang, Soo Young Byun, Inhee Choi, Anne Laure Pham Hung d'Alexandry d'Orengiani, David Shum, Ji-Young Min, Marc P. Windisch doi: https://doi.org/10.1101/2020.02.25.965582 Abstract In 2015, the Middle East respiratory syndrome coronavirus (MERS-CoV) reached the Republic of Korea, resulting from nosocomial transmission, and was the largest epidemic outside of the Arabian Peninsula. To date, despite various strategies to identify CoV interventions, there are only limited therapeutic options available. To address these unmet medical needs, we used a South Korean MERS-CoV clinical isolate and screened 5,406 compounds, including US Food and Drug Administration (FDA)-approved drugs and bioactive molecules, confirmed 221 hits by dose-response curve analysis in the primary assay, and selected 54 hits with a therapeutic index (TI) greater than 6. Time-of-addition studies with 12 FDA-approved drugs demonstrated that eight and four therapeutics act on the early- and late stages of the viral life cycle, respectively. Among the early acting drugs, three therapeutics with a TI greater than 100 were cardiotonic agents. Together, our results identify potential therapeutic options for treatment of MERS-CoV infections and could provide a basis for a wider range of coronaviruses, including the currently emerging coronavirus disease 2019 (COVID-19) outbreak. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    43浏览量
    原文链接